Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PrNMI是一种针对外周限制性大麻素1受体(CB1R)的高效、口服活性激动剂。它展现出显著的镇痛特性,有效抑制化疗引起的周围神经病痛症状及癌症引起的骨痛。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,350 | 现货 | ||
5 mg | ¥ 5,630 | 现货 | ||
10 mg | ¥ 7,790 | 现货 | ||
25 mg | ¥ 11,200 | 现货 | ||
50 mg | ¥ 13,800 | 现货 | ||
100 mg | ¥ 17,500 | 现货 | ||
500 mg | ¥ 38,500 | 现货 |
产品描述 | PrNMI is a highly effective and orally active agonist targeting the peripherally restricted cannabinoid 1 receptor (CB1R). It exhibits pronounced analgesic properties, efficiently suppressing both chemotherapy-induced peripheral neuropathy pain symptoms and cancer-induced bone pain. |
体外活性 | PrNMI (1 nM-1 μM; 24小时) 对体外66.1乳腺肿瘤细胞的活性无影响。[2] |
体内活性 |
PrNMI (0.25 mg/kg; Intraplantar ipsilateral administration; i.p.; CIPN rat model) causes significantly greater suppression in mechanical but not cold allodynia on the ipsilateral paw compared to contralateral paw or systemic administration at 2 h post-PrNMI.[1] PrNMI (3.0 mg/kg; i.g.; 48 h; CIPN rat model) dose-dependently suppresses CIPN symptoms in both male and female rats and is equally effective in male and female rats after oral administration.[1] PrNMI (1 mg/kg; p.o.; 48 h; CIPN rat model) exhibits anti-allodynic effects in CIPN mediated mainly by CB1Rs.[1] PrNMI (1 mg/kg; p.o.; daily for two weeks;) shows no significant tolerance to suppression of both mechanical and cold allodynia during the two-week testing period.[1] PrNMI (0.1, 0.3, and 0.6 mg/kg; i.p.) results in a significant, time-related reduction of flinching but not guarding in a dose-dependent manner. This suppression of flinching starts 1 hour post-injection and persists for at least 5 hours.[2] |
分子量 | 409.56 |
分子式 | C29H31NO |
CAS No. | 1541244-33-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 1mg/ml, Sonication is recommended.
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PrNMI 1541244-33-0 GPCR/G Protein Cannabinoid Receptor Inhibitor inhibitor inhibit